This article features Laura Niklason, MD, PhD, co-founder of Humacyte and a former faculty member at Duke Anesthesiology who is now at Yale.
By Duke Medicine News and Communications
DURHAM, N.C. – In a first-of-its-kind operation in the United States, a team of doctors at Duke University Hospital helped create a bioengineered blood vessel and transplanted it into the arm of a patient with end-stage kidney disease.
The procedure, the first U.S. clinical trial to test the safety and effectiveness of the bioengineered blood vessel, is a milestone in the field of tissue engineering. The new vein is an off-the-shelf, human cell-based product with no biological properties that would cause organ rejection. READ MORE.